FDA Panel Signals Move to Loosen Rules on Controversial Peptides
An FDA advisory panel voted to loosen restrictions on controversial peptides such as BPC-157, TB-500, and KPV, potentially allowing specialized pharmacies to produce them and move toward prescription access, despite limited human safety data and ongoing scrutiny; the decision is non-final and faces further debate.